



PATENT CASE CV01489K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 30 2003
TECH CENTER 1600 0900

-----X
In re Application of:
Harry R. Davis et al

For Patent For:
Combinations of Peroxisome Proliferator-
Activated Receptor (PPAR) Activator(s) and
Sterol Absorption Inhibitor(s) and
Treatments for Vascular Indications

Examiner: To Be Assigned

Art Unit: 1619

Serial No.: 10/057,323

Filing Date: January 25, 2002

-----X
Schering-Plough Corporation
Kenilworth, New Jersey 07033-0530

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

It is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. A copy of each cited document is attached.

A copy of the PCT International Search Report dated April 23, 2003 for corresponding PCT Application No. PCT/US02/02009 is submitted for the Examiner's review.

No fee is believed to be due, however, if any fee is due the Commissioner is authorized to charge Deposit Account Number 19-0365 for any fees deemed necessary for consideration and entry of this Information Disclosure Statement into the file record.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on May 22, 2003

Ann Marie Cannoni
Registered Representative

Signature

5/22/03
Date

Respectfully submitted,

Ann Marie Cannoni
Reg. No. 35,972
Attorney for Applicants
(908) 298-5024

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.: CV01489K APPLICANT: Harry R. Davis, et al. FILING DATE: 01/25/2002		SERIAL NO.: 10/057,323 GROUP: 1619			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 99/08501	2/25/99	PCT			
	AM						
	AN						
	AO						
	AP						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AQ	"Study showed ezetimibe significantly reduced levels of LDL cholesterol or "bad" cholesterol in patients" <i>Schering Press Release</i> 1-3 (2001)					
	AR	Kosoglou <i>et al.</i> , "Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe" <i>Atherosclerosis</i> (2):3(2001)					
	AS	Davis <i>et al.</i> , "The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in Combination with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Dogs" <i>Metabolism</i> 50(10):1234-1241(2001)					
	AT						
	AU						
	AV						
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							